Shanghai Henlius Biotech reports August stability in capital structure

Shanghai Henlius Biotech, Inc. reported its monthly movements in securities for the period ending August 31, 2025, revealing no changes to its total issued H shares or unlisted ordinary shares. The number of issued H shares remained at 163,428,541, with unlisted shares stable at 380,066,312. The total authorised/registered share capital at month-end stood at RMB 543,494,853.

During August, the company saw some activity in its 2025 H Share Option Scheme. There were 67,500 new options granted, increasing the outstanding options to 7,039,500, while 5,000 options lapsed. No new shares were issued from option exercises, nor were any treasury shares transferred. Additionally, under the 2025 H Share RSU Scheme, 87,500 RSUs were granted, with 5,000 lapsing during the month. As of month-end, 7,059,500 RSUs, representing the contingent right to receive restricted shares, remained granted and not lapsed.

Overall, the report indicates a period of relative stability in the company’s capital structure, with minor adjustments related to employee incentive schemes.